Related Topics News -

     
 Title only   |   Print 
     
《大行》高盛:中國生物醫藥產品出海授權趨勢屬結構性 升中生(01177.HK)目標價至6.19元

2025-07-09T  
《大行》交銀國際列出南向資金對港股各行業持倉分佈及配置集中度(表)

2025-07-04T  
《大行》交銀國際:南向資金近月主力配置集中醫療和金融板塊 反映對高息防禦價值重視

2025-07-04T  
《大行》野村:百濟神州臨床前研究數量今年增至85個 正進行96項臨床實驗

2025-06-27T  
港股爆「抽水潮」眾安曾挫一成 宏橋續破頂 創新藥股受壓榮昌曾瀉25%

2025-06-26T  
《港股》恆指高收158點 芯片及地產股造高 太平洋航運飆兩成

2025-06-23T  
《大行》交銀國際對醫藥股投資評級及目標價(表)

2025-06-23T  
《大行》大華繼顯:行業進入加速增長新階段 首選翰森製藥信達生物中國生物製藥

2025-06-19T  
據報武田中國總裁單國洪月底離職 疑跳槽至百濟神州

2025-06-17T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.